Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:CTSO NASDAQ:VANI OTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.09+2.7%$2.10$0.76▼$2.73$78.86M1.39115,040 shs63,723 shsCTSOCytosorbents$0.85-5.0%$1.06$0.71▼$1.61$53.29M1.19191,301 shs269,149 shsVANIVivani Medical$1.23+0.4%$1.35$0.91▼$1.80$72.57M2.99106,652 shs51,790 shsVASOVaso$0.12+4.4%$0.13$0.11▼$0.32$21.09M1.5776,230 shs91,330 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+3.05%-13.62%-9.38%+22.29%+58.59%CTSOCytosorbents-17.23%-17.23%-14.05%+5.29%-14.87%VANIVivani Medical+0.83%-3.17%-21.29%+7.02%-11.59%VASOVaso-5.82%-4.33%-10.72%-14.89%-54.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical1.269 of 5 stars0.03.00.04.20.61.70.6CTSOCytosorbents2.1278 of 5 stars3.33.00.00.02.60.00.6VANIVivani Medical2.1955 of 5 stars3.53.00.00.01.71.70.0VASOVaso1.1301 of 5 stars0.05.00.00.00.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ACTSOCytosorbents 2.50Moderate Buy$5.50497.83% UpsideVANIVivani Medical 3.00Buy$4.00225.20% UpsideVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VASO, APYX, VANI, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.008/8/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/21/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/25/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.61N/AN/A$0.20 per share10.23CTSOCytosorbents$36.11M1.60N/AN/A$0.18 per share5.11VANIVivani MedicalN/AN/AN/AN/A$0.08 per shareN/AVASOVaso$86.77M0.24$0.01 per share12.07$0.15 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)CTSOCytosorbents-$20.72M-$0.17N/AN/AN/A-25.58%-111.97%-29.00%11/6/2025 (Estimated)VANIVivani Medical-$23.49M-$0.45N/AN/AN/AN/A-194.66%-68.64%N/AVASOVaso$950K-$0.01N/A∞N/A-0.35%-1.14%-0.38%N/ALatest VASO, APYX, VANI, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VANIVivani Medical-$0.10-$0.12-$0.02-$0.12N/AN/A8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 million8/7/2025Q2 2025CTSOCytosorbents-$0.07-$0.05+$0.02$0.03$9.79 million$9.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95CTSOCytosorbents1.242.341.96VANIVivani MedicalN/A1.301.30VASOVasoN/A1.511.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CTSOCytosorbents32.87%VANIVivani Medical6.78%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%CTSOCytosorbents7.30%VANIVivani Medical46.40%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionableCTSOCytosorbents22062.76 million58.18 millionOptionableVANIVivani Medical2059.24 million31.76 millionOptionableVASOVaso260175.74 million97.54 millionNot OptionableVASO, APYX, VANI, and CTSO HeadlinesRecent News About These CompaniesVaso Stock Down Following Q2 Earnings as Revenue and Margins Fall1 hour ago | zacks.comVaso (OTCMKTS:VASO) versus Anteris Technologies Global (NASDAQ:AVR) Head to Head ContrastAugust 21 at 3:47 AM | americanbankingnews.comPfizer Provides Update on Phase 3 Inclacumab Study for the Treatment of People with Sickle Cell DiseaseAugust 19 at 2:15 AM | pipelinereview.comPInclacumab Misses Endpoint In Sickle Cell Disease TrialAugust 19 at 2:15 AM | empr.comEPfizer's sickle cell drug fails late-stage trialAugust 15, 2025 | msn.comPfizer's sickle-cell treatment efforts falter as drug fails studyAugust 15, 2025 | msn.comVaso Corporation reports Q2 revenue $20M vs. $20.2M last yearAugust 14, 2025 | msn.comVaso Corporation Announces Financial Results for Second Quarter of 2025August 14, 2025 | finance.yahoo.comVaso Corporation Announces Financial Results for Second Quarter of 2025 | VASO Stock NewsAugust 14, 2025 | gurufocus.comFirst Patient Dosed In Clinical Trial Of Therapy For Sickle DiseaseAugust 8, 2025 | msn.comGreece stuns USA to reach women’s water polo World Championship finalJuly 23, 2025 | neoskosmos.comNLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26, 2025 | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comOral inhibitor rilzabrutinib granted FDA orphan drug status for SCDJune 5, 2025 | sicklecellanemianews.comSUS FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell diseaseJune 5, 2025 | pharmabiz.comPSanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell diseaseJune 4, 2025 | medicaldialogues.inMPress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseJune 3, 2025 | taiwannews.com.twTSickle cell disease and knee joint pain: Why steriods aren’t always the best optionMay 30, 2025 | punchng.comPVaso Corporation Registered ShsMay 20, 2025 | markets.businessinsider.comVaso Stock Slips Post Q1 Earnings Despite Record Revenue GrowthMay 20, 2025 | zacks.comMedia Sentiment Over TimeVASO, APYX, VANI, and CTSO Company DescriptionsApyx Medical NASDAQ:APYX$2.08 +0.06 (+2.71%) Closing price 03:58 PM EasternExtended Trading$2.00 -0.09 (-4.27%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Cytosorbents NASDAQ:CTSO$0.85 -0.04 (-5.02%) Closing price 03:59 PM EasternExtended Trading$0.86 +0.01 (+1.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Vivani Medical NASDAQ:VANI$1.23 +0.01 (+0.41%) Closing price 03:58 PM EasternExtended Trading$1.23 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Vaso OTCMKTS:VASO$0.12 +0.01 (+4.44%) As of 03:11 PM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Rocket Lab Stock: Breakout Brewing or Time for Patience? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access